UNITED THERAPEUTICS CorpUTHR
What UNITED THERAPEUTICS Corp does.
Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension ( PAH ), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.
As a public benefit corporation ( PBC ), we aim to deliver meaningful impacts for our patients, our people, our shareholders, and other stakeholders. Our public benefit purpose, as outlined in our charter and approved by our shareholders, is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs .
• Remodulin® (treprostinil) Injection ( Remodulin ); and the Remunity® and RemunityPRO™ Pumps for Remodulin ( Remunity );
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.7B | $1.9B | $2.3B | $2.9B | $3.2B |
| Net income | — | $475.8M | $727.3M | $984.8M | $1.2B | $1.3B |
| Free cash flow | $696.4M | $477.4M | $663.7M | $747.6M | $1.1B | $1.0B |
More on UTHR.
- UNITED THERAPEUTICS Corp summary
- UNITED THERAPEUTICS Corp financial statements
- UNITED THERAPEUTICS Corp key metrics
- UNITED THERAPEUTICS Corp health scores and style box
- UNITED THERAPEUTICS Corp earnings
- UNITED THERAPEUTICS Corp dividends
- UNITED THERAPEUTICS Corp valuation
- UNITED THERAPEUTICS Corp ownership and insiders
- UNITED THERAPEUTICS Corp peers
Figures from UNITED THERAPEUTICS Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.